Clinical Trials Logo

Filter by:
NCT ID: NCT05185960 Completed - Blood Sugar Clinical Trials

Comparison of the Postprandial Glycemic and Insulinemic Response of ALLSWEET When Taken Alone or When Added to Sucrose

Start date: September 15, 2021
Phase: N/A
Study type: Interventional

This study will explore the postprandial glycemic response of ALLSWEET®, a non-GMO certified allulose, when consumed alone or with sucrose, compared to the consuming sucrose alone. On 3 separate days, subjects will consume in random order ALLSWEET® alone, ALLSWEET® added to sucrose, or sucrose alone. Blood samples for glucose and insulin analysis with be taken for 2 hours following consumption of the beverages.

NCT ID: NCT05183607 Completed - Clinical trials for Nutritional Deficiency

A Cardiac Surgery Virtual Nutrition Intervention Program Feasibility Study-VIP Study Protocol

Start date: January 28, 2022
Phase: N/A
Study type: Interventional

This feasibility study will look to identify the impact that a remote/virtual nutritional intervention can have on nutrition literacy and knowledge retention of the cardiac surgery patient.

NCT ID: NCT05182840 Completed - Clinical trials for Kidney Disease, Chronic

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Start date: January 11, 2022
Phase: Phase 2
Study type: Interventional

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT05181280 Completed - Health Behavior Clinical Trials

Moms on Media Study

MOMS
Start date: November 15, 2020
Phase: N/A
Study type: Interventional

This research will explore the impact of digital technology, specifically social media, on the health behaviours of mothers in the postpartum period by conducting an experimental study to test the effect of social media messaging on body dissatisfaction, eating attitudes and behaviours, and physical activity intentions and behaviours among postpartum mothers. The primary objective is to determine the extent to which body image messaging targeting mothers, compared with the control, result in feelings of body dissatisfaction and poorer eating attitudes and behaviours, and increased physical activity intention immediately following the 5-day exposure period. The secondary objective is to determine the sustained impact of the body image messaging compared to control at 1-month follow-up.

NCT ID: NCT05180968 Completed - Clinical trials for End Stage Renal Disease

DIalysis Symptom COntrol-Pruritus Outcome Trial

DISCO-POT
Start date: August 2, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether or not a medication called nabilone, which is a synthetic (non-natural) medication derived from cannabis, compared to placebo improves symptoms of itch in hemodialysis as measured by visual analog scales.

NCT ID: NCT05180656 Completed - Breast Cancer Clinical Trials

Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer Survivors

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to assess the feasibility of a remotely-delivered yoga intervention for breast cancer survivors.

NCT ID: NCT05179031 Completed - Glycemic Response Clinical Trials

Assessment of the Glycemic Responses to Nutritional Products

GLIN#1
Start date: January 4, 2022
Phase: N/A
Study type: Interventional

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

NCT ID: NCT05176860 Completed - Breast Cancer Clinical Trials

Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

This is a feasibility study investigating the image quality of a new, high-performance cone beam CT (CBCT) used for on-couch imaging during radiotherapy treatments.

NCT ID: NCT05175742 Completed - Covid19 Vaccine Clinical Trials

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

Start date: August 17, 2021
Phase: Phase 2
Study type: Interventional

The Vaccine Product, PTX-COVID19-B mRNA Humoral Vaccine, is intended for prevention of COVID-19 in a general population. This study is designed to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B compared to Pfizer-BioNTech COVID-19 vaccine in healthy seronegative adults aged 18 to 64.

NCT ID: NCT05174663 Completed - Clinical trials for Hypercholesterolemia

Investigating the Dose Response of an Almond-enriched Diet on Optimizing HDL-C in a Population With Hypercholesterolemia

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

This study will determine the quantity of almonds (1.5 oz or 2.5 oz) consumed as a snack that will provide optimal increases in HDL-C levels.